Literature DB >> 15219815

Adenosine uptake inhibitors.

Tohru Noji1, Akira Karasawa, Hideaki Kusaka.   

Abstract

Adenosine is a purine nucleoside and modulates a variety of physiological functions by interacting with cell-surface adenosine receptors. Under several adverse conditions, including ischemia, trauma, stress, seizures and inflammation, extracellular levels of adenosine are increased due to increased energy demands and ATP metabolism. Increased adenosine could protect against excessive cellular damage and organ dysfunction. Indeed, several protective effects of adenosine have been widely reported (e.g., amelioration of ischemic heart and brain injury, seizures and inflammation). However, the effects of adenosine itself are insufficient because extracellular adenosine is rapidly taken up into adjacent cells and subsequently metabolized. Adenosine uptake inhibitors (nucleoside transport inhibitors) could retard the disappearance of adenosine from the extracellular space by blocking adenosine uptake into cells. Therefore, it is expected that adenosine uptake inhibitors will have protective effects in various diseases, by elevating extracellular adenosine levels. Protective or ameliorating effects of adenosine uptake inhibitors in ischemic cardiac and cerebral injury, organ transplantation, seizures, thrombosis, insomnia, pain, and inflammatory diseases have been reported. Preclinical and clinical results indicate the possibility of therapeutic application of adenosine uptake inhibitors. Copyright 2004 Elsiever B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15219815     DOI: 10.1016/j.ejphar.2004.05.003

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  25 in total

1.  A role of erythrocytes in adenosine monophosphate initiation of hypometabolism in mammals.

Authors:  Isadora Susan Daniels; Jianfa Zhang; William G O'Brien; Zhenyin Tao; Tomoko Miki; Zhaoyang Zhao; Michael R Blackburn; Cheng Chi Lee
Journal:  J Biol Chem       Date:  2010-04-29       Impact factor: 5.157

Review 2.  P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use.

Authors:  Nicholas B Norgard; James J DiNicolantonio
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091

3.  Adenosine negatively regulates duodenal motility in mice: role of A(1) and A(2A) receptors.

Authors:  M G Zizzo; M Mastropaolo; L Lentini; F Mulè; R Serio
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

Review 4.  Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?

Authors:  V Kumar
Journal:  Purinergic Signal       Date:  2012-12-28       Impact factor: 3.765

5.  Adenosinergic signaling inhibits oxalate transport by human intestinal Caco2-BBE cells through the A2B adenosine receptor.

Authors:  Daniel Jung; Altayeb Alshaikh; Sireesha Ratakonda; Mohamed Bashir; Ruhul Amin; Sohee Jeon; Jan Stevens; Sapna Sharma; Wahaj Ahmed; Mark Musch; Hatim Hassan
Journal:  Am J Physiol Cell Physiol       Date:  2018-07-18       Impact factor: 4.249

6.  Adenosine Release Evoked by Short Electrical Stimulations in Striatal Brain Slices is Primarily Activity Dependent.

Authors:  Megan L Pajski; B Jill Venton
Journal:  ACS Chem Neurosci       Date:  2010-10-01       Impact factor: 4.418

7.  Adenosine neuromodulation and traumatic brain injury.

Authors:  T A Lusardi
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

8.  Biosensor measurement of purine release from cerebellar cultures and slices.

Authors:  Mark Wall; Robert Eason; Nicholas Dale
Journal:  Purinergic Signal       Date:  2010-05-25       Impact factor: 3.765

9.  Adenosine signalling at immature parallel fibre-Purkinje cell synapses in rat cerebellum.

Authors:  Alison Atterbury; Mark J Wall
Journal:  J Physiol       Date:  2009-08-03       Impact factor: 5.182

10.  Nucleoside map of the human central nervous system.

Authors:  Zsolt Kovács; Arpád Dobolyi; Gábor Juhász; Katalin A Kékesi
Journal:  Neurochem Res       Date:  2009-10-24       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.